 Dicerna Pharmaceuticals Inc NASDAQ: DRNA has announced new data from preclinical studies of its GalXC-Plus RNAi technology demonstrating its potential to deliver messenger RNA mRNA knockdown against prespecified gene targets across the central nervous system CNS and to specific CNS cell types. Data from a preclinical mouse study showed that a single dose of an unconjugated GalXC-Plus molecule produced by the ALDH2 gene resulted in dose-dependent reductions of up to 92 knockdown in target mRNA and lasted through the trial conclusion at 28 days. 